Skip to content
Research Article Open access CC BY 4.0

Dementia Diagnosis and Alternate Treatment: A Recent Update on Treatment Options

Uma D. Gupta, Tasnuva Nuhat Shafin, Nuzhat Rahman, Elora Chakraborty, Manisha Deb, Tahira Ferdous

Asian Journal of Medicine and Health · pp. 14–21 · Published 18 Jul 2023

10.9734/ajmah/2023/v21i10874

Abstract

Dementia is a global health burden identified by the World Health Organization in its global action plan on the public health response to dementia 2017-2025. Our study aims to determine the efficacy of treatment options in Alzheimer’s disease and related dementia (ADRD). The initiation of dementia treatment has consistently posed a significant dilemma for healthcare professionals, necessitating careful consideration when selecting the appropriate group of medications to commence therapy, considering the specific type of treatment required. To conduct our study, we searched PubMed Central and the Cochrane database to identify comparative trials that compared different dementia treatment options. Our objective was to evaluate the effectiveness of various treatment approaches across different types of dementia. In total, we reviewed over 40 papers that provided valuable insights into the comparative outcomes of these treatment options. In our analysis, we have found mild to moderate cognitive dysfunction (MMSE 19 to 26) and newly diagnosed Alzheimer's disease can be treated with a trial of Cholinesterase inhibitors (Donepezil, Galantamine, and Rivastigmine); choice can be based on clinician and/or patient preference, as efficacy is similar. Moderate to advanced dementia (MMSE 10 to 18): Memantine (10 mg twice daily) is a suggested option with Cholinesterase inhibitors. In conclusion, it is evident that the available options for dementia medication are inherently limited, while the resources allocated to evaluate further treatment alternatives remain constrained. As a result, there is an urgent need to prioritize additional research and comprehensive assessment in this field.

Dementia diagnosis dementia treatment Alzheimer’s disease

References (22)

  1. 1 The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease [DOI]
  2. 2 Cholinesterase inhibitors for Alzheimer's disease [DOI]
  3. 3 Practice parameter: Management of dementia (an evidence-based review) [RETIRED] [DOI]
  4. 4 Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving Donepezil [DOI]
  5. 5 Donepezil for dementia due to Alzheimer's disease [DOI]
  6. 6 Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial [DOI]
  7. 7 Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup [DOI]
  8. 8 Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline [DOI]
  9. 9 ω-3 Fatty Acid Treatment in 174 Patients With Mild to Moderate Alzheimer Disease: OmegAD Study [DOI]
  10. 10 Glycine and N-Methyl-d-Aspartate Receptors: Physiological Significance and Possible Therapeutic Applications [DOI]
  11. 11 High-Dose B Vitamin Supplementation and Cognitive Decline in Alzheimer Disease [DOI]
  12. 12 Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials [DOI]
  13. 13 Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. [DOI]
  14. 14 Mixed Dementia [DOI]
  15. 15 Current Pharmacologic Treatment of Dementia: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians [DOI]
  16. 16 A resurrection of aducanumab for Alzheimer's disease [DOI]
  17. 17 Evaluation of Aducanumab for Alzheimer Disease [DOI]
  18. 18 Galantamine for vascular cognitive impairment [DOI]
  19. 19 Screening for Dementia: Recommendation and Rationale [DOI]
  20. 20 Treatment of Alzheimer's Disease [DOI]
  21. 21 Rivastigmine for Alzheimer's disease [DOI]
  22. 22 Vitamin E for Alzheimer's dementia and mild cognitive impairment [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

67

Page views

0

PDF downloads

19

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.